REALM - RANDOMIZED, OBSERVATIONAL STUDY OF ENTECAVIR TO ASSESS LONG-TERM OUTCOMES ASSOCIATED WITH NUCLEOSIDE/NUCLEOTIDE MONOTHERAPY FOR PATIENTS WITH CHRONIC HIV INFECTION Trademark

Trademark Overview

On Tuesday, May 18, 2010, a trademark application was filed for REALM - RANDOMIZED, OBSERVATIONAL STUDY OF ENTECAVIR TO ASSESS LONG-TERM OUTCOMES ASSOCIATED WITH NUCLEOSIDE/NUCLEOTIDE MONOTHERAPY FOR PATIENTS WITH CHRONIC HIV INFECTION with the United States Patent and Trademark Office. The USPTO has given the REALM - RANDOMIZED, OBSERVATIONAL STUDY OF ENTECAVIR TO ASSESS LONG-TERM OUTCOMES ASSOCIATED WITH NUCLEOSIDE/NUCLEOTIDE MONOTHERAPY FOR PATIENTS WITH CHRONIC HIV INFECTION trademark a serial number of 85041166. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, June 16, 2014. This trademark is owned by Bristol-Myers Squibb Company. The REALM - RANDOMIZED, OBSERVATIONAL STUDY OF ENTECAVIR TO ASSESS LONG-TERM OUTCOMES ASSOCIATED WITH NUCLEOSIDE/NUCLEOTIDE MONOTHERAPY FOR PATIENTS WITH CHRONIC HIV INFECTION trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Medical and scientific research, namely, conducting clinical trials and clinical studies relating to pharmaceutical preparations for human use
realm - randomized, observational study of entecavir to assess long-term outcomes associated with nucleoside/nucleotide monotherapy for patients with chronic hiv infection

General Information

Serial Number85041166
Word MarkREALM - RANDOMIZED, OBSERVATIONAL STUDY OF ENTECAVIR TO ASSESS LONG-TERM OUTCOMES ASSOCIATED WITH NUCLEOSIDE/NUCLEOTIDE MONOTHERAPY FOR PATIENTS WITH CHRONIC HIV INFECTION
Filing DateTuesday, May 18, 2010
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, June 16, 2014
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, March 15, 2011

Trademark Statements

Disclaimer with Predetermined Text"RANDOMIZED, OBSERVATIONAL STUDY OF ENTECAVIR TO ASSESS LONG-TERM OUTCOMES ASSOCIATED WITH NUCLEOSIDE/NUCLEOTIDE MONOTHERAPY FOR PATIENTS WITH CHRONIC HIV INFECTION"
Goods and ServicesMedical and scientific research, namely, conducting clinical trials and clinical studies relating to pharmaceutical preparations for human use

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateSaturday, May 22, 2010
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameBristol-Myers Squibb Company
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressNew York, NY 10154
Party NameBristol-Myers Squibb Company
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNew York, NY 10154

Trademark Events

Event DateEvent Description
Monday, June 16, 2014ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED
Monday, June 16, 2014ABANDONMENT - NO USE STATEMENT FILED
Tuesday, December 10, 2013NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Sunday, December 8, 2013EXTENSION 5 GRANTED
Friday, November 8, 2013EXTENSION 5 FILED
Friday, November 8, 2013TEAS EXTENSION RECEIVED
Tuesday, June 4, 2013NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, June 3, 2013EXTENSION 4 GRANTED
Friday, May 10, 2013EXTENSION 4 FILED
Friday, May 10, 2013TEAS EXTENSION RECEIVED
Wednesday, April 3, 2013TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, November 14, 2012NOTICE OF APPROVAL OF EXTENSION REQUEST MAILED
Tuesday, November 13, 2012EXTENSION 3 GRANTED
Thursday, November 8, 2012EXTENSION 3 FILED
Thursday, November 8, 2012TEAS EXTENSION RECEIVED
Tuesday, May 1, 2012NOTICE OF APPROVAL OF EXTENSION REQUEST MAILED
Sunday, April 29, 2012EXTENSION 2 GRANTED
Tuesday, April 17, 2012EXTENSION 2 FILED
Tuesday, April 17, 2012TEAS EXTENSION RECEIVED
Saturday, October 8, 2011NOTICE OF APPROVAL OF EXTENSION REQUEST MAILED
Friday, October 7, 2011EXTENSION 1 GRANTED
Monday, October 3, 2011EXTENSION 1 FILED
Tuesday, October 4, 2011CASE ASSIGNED TO INTENT TO USE PARALEGAL
Monday, October 3, 2011TEAS EXTENSION RECEIVED
Tuesday, May 10, 2011NOA MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, April 19, 2011ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Tuesday, April 19, 2011TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Tuesday, March 15, 2011PUBLISHED FOR OPPOSITION
Wednesday, February 23, 2011NOTICE OF PUBLICATION
Friday, February 4, 2011LAW OFFICE PUBLICATION REVIEW COMPLETED
Wednesday, February 2, 2011APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, February 2, 2011EXAMINER'S AMENDMENT ENTERED
Wednesday, February 2, 2011ASSIGNED TO LIE
Wednesday, February 2, 2011EXAMINERS AMENDMENT MAILED
Wednesday, February 2, 2011EXAMINERS AMENDMENT -WRITTEN
Thursday, January 27, 2011TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, January 27, 2011CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, January 27, 2011TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, August 11, 2010NON-FINAL ACTION MAILED
Tuesday, August 10, 2010NON-FINAL ACTION WRITTEN
Friday, July 30, 2010ASSIGNED TO EXAMINER
Saturday, May 22, 2010NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Friday, May 21, 2010NEW APPLICATION ENTERED IN TRAM

Related Keywords

nucleotide nucleoside associated monotherapy patients infection chronic outcomes term observational clinical relating pharmaceutical preparations human studies trials research namely conducting